Suchergebnisse - "2494G1JF75"

PubPharm (2.348)

81

Mechanisms and Extent of Enhanced Passive Permeation by Colloidal Drug Particles

enthalten in: Molecular pharmaceutics | 2022

von Narula, A. | Sabra, R. | Li, N.

82

Long-acting HIV fusion inhibitor albuvirtide combined with ritonavir-boosted lopinavir for HIV-1-infected patients after failing the first-line antiretroviral therapy : 48-week randomized, controlled, phase 3 non-inferiority TALENT study

enthalten in: The Journal of infection | 2022

von Su, B. | Yao, C. | Zhao, Q. | +37

83

An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-β-1a, and hydroxychloroquine in hospitalized patients with COVID-19 : final results

enthalten in: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases | 2022

von Ader, F. | DisCoVeRy Study Group

84

Short-term Pregnancy Outcomes After Nirmatrelvir-Ritonavir Treatment for Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

enthalten in: Obstetrics and gynecology | 2022

von Loza, A. | Farias, R. | Gavin, N. | +3

85

Emerging Therapies for COVID-19 : The Value of Information From More Clinical Trials

enthalten in: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | 2022

von Dijk, S. | Krijkamp, E. | Kunst, N. | +3

86

High-cited favorable studies for COVID-19 treatments ineffective in large trials

enthalten in: Journal of clinical epidemiology | 2022

von Ioannidis, J.

87

Should RECOVERY have used response adaptive randomisation? Evidence from a simulation study

enthalten in: BMC medical research methodology | 2022

von Sirkis, T. | Jones, B. | Bowden, J.

88

Insights from a computational analysis of the SARS-CoV-2 Omicron variant : Host-pathogen interaction, pathogenicity, and possible drug therapeutics

enthalten in: Immunity, inflammation and disease | 2022

von Parvez, M. | Saha, M. | Ibrahim, M. | +4

89

The addition of lopinavir-ritonavir to carfilzomib-based triplets can induce meaningful clinical response in carfilzomib-refractory myeloma patients : a single-center experience

enthalten in: Leukemia & lymphoma | 2022

von Bennett, R. | Chan, H. | Henderson, R. | +4

90

Efficacy and safety of favipiravir plus interferon-beta versus lopinavir/ritonavir plus interferon-beta in moderately ill patients with COVID-19 : A randomized clinical trial

enthalten in: Journal of medical virology | 2022

von Hassaniazad, M. | Farshidi, H. | Gharibzadeh, A. | +4